tbuckley/cabot-search huggingface dataset:
OC-089 One-year experience of a hepato-pancreatobiliary cancer service in a large district general hospital: impact on local cancer care delivery
Authors: R Kia, A Boon, R Faizallah, A Singhal
Journal: Gut (2010)

<h3>Introduction</h3> Dedicated hepato-pancreatobiliary (HPB) cancer teams are rare outside tertiary centres. Patients with HPB cancer pose complex clinical problems requiring close liaison between primary, secondary and tertiary care. Reconfiguration of HPB cancer services in the Mersey region has lead to standardisation of care via referral to Regional Specialist Centres (RSC). However, local cancer care delivery remains fragmented and limited by the variable expertise of various clinical teams involved. We report the impact of a new combined consultant and nurse-led service established to improve overall management and facilitate local ownership of care. <h3>Methods</h3> Our local HPB cancer service (HPBCS) was established on 1 June 2008, the first of such service in a large DGH (catchment population: 360 000) in the Mersey region. All patients with suspected HPB cancer were referred to the local HPB Team comprising of two consultants with interest in HPB diseases (one nominated lead clinician) and a nurse specialist. Patients were case managed as per the Mersey and Cheshire Cancer Network Protocol, with discussion at the appropriate RSC MDT meetings (pancreas and hepatobiliary). The local HPBCS team meets weekly to discuss all new referrals, MDT outcomes and urgent management issues. There is also a weekly HPB nurse-led clinic that provides urgent feedback of RSC decisions, rapid access for symptom control and ensures continuity of care. <h3>Results</h3> 279 patients were referred to the HPBCS between 1 June 08 and 1 June 09: 175 for suspected pancreatic cancer (PC), 104 for hepatobiliary cancer (HC). This compares with 51 for suspected PC over a 6-month period pre-HPBCS and 26 for suspected HC a year pre-HPBCS, representing an annual increase of 72% and 300%, respectively. The outcomes of discussion at the RSC for suspected PC were: inoperable PC (59/175), operable PC (24/175), IPMN (45/175), benign lesions (22/175), pancreatitis (15/175) and pseudocysts (10/175), while for HC: hepatocellular carcinoma (34/104), gallbladder cancer (13/104), cholangiocarcinoma (9/104), liver metastases of unknown primary (2/104), benign liver lesions (23/104) and liver lesions of unknown significance (21/104). 23.7% of cases (45 IPMN, 21 liver lesions of unknown significance) were referred back for local surveillance contributing to an ever expanding pool of patients under the local HPB team. Nearly all cases were referred to the RSCs within 2 weeks of referral. <h3>Conclusion</h3> (1) Since commencement of HPBCS, there is a sharp increase of suspected HPB cancers identified and referred on to RSCs, leading to timely and uniform care as per regional network guidelines. (2) All Wirral patients with suspected HPB cancer are now case managed by the HPBCS with local ownership of care.
Characterization of Non-Expanded Mesenchymal Progenitors Cells from Normal Adult Human Bone Marrow.
Authors: Boiret Nathalie, Rapatel Chantal, Veyrat-Masson Richard, Guillouard Laurent, Guerin Jean Jacques, Pigeon Pascale, Descamps Stephane, Boisgard Stephane, Berger G. Marc
Journal: Blood (2004)
The ambition of the <i>European Respiratory Journal</i> continues: chapter 5
Authors: Marc Humbert, Anh Tuan Dinh-Xuan, Elin L. Reeves, Matthew G. Broadhead, Neil J. Bullen
Journal: European Respiratory Journal (2017)

Happy New Year! As 2017 begins, so too does the final year of the current editorial board's mandate. Welcome to our annual look back at some of the highlights of our past 12 months of publishing, and forward to some of the new developments 2017 will see for the European Respiratory Journal . A look back at the highlights from the ERJ in 2016, and forward to new developments that will arrive in 2017 <http://ow.ly/Tezb3074Jfw>
Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide
Authors: Aaron T. Gerds, Alan F. List, Aristoteles Giagounidis, Eva Hellström-Lindberg, Jack Shiansong Li, Arlene S. Swern, Mary M. Sugrue, Pierre Fenaux, Mikkael A. Sekeres
Journal: Blood (2015)
Smudge Cells on Routine Blood Smear Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test.
Authors: Grzegorz S. Nowakowski, James D. Hoyer, Tait D. Shanafelt, Susan M. Geyer, Betsy LaPlant, Timothy G. Call, Diane F. Jelinek, Clive S. Zent, Neil E. Kay
Journal: Blood (2006)
Abstract POSTER-TECH-1101: Characterization of genomic landscapes of BRCA1 and BRCA2 implicated ovarian cancer specimens from a founder french canadian population
Authors: Eman AlShehri, Moria Belanger, Suzanna Arcand, Kathleen Klein Oros, Celia Greenwood, Patricia N. Tonin
Journal: Clinical Cancer Research (2015)

Abstract Although molecular genetic profiling of ovarian cancers harboring germline BRCA1/BRCA2 mutations suggest that pathways in common with sporadic cases are involved in the pathogenesis of the disease, overall survival differs between BRCA1, BRCA2 and sporadic disease. To further dissect molecular pathways involved, which could account for differences in pathogenesis of the disease, we have investigated genomic landscapes in the BRCA1 and BRCA2 mutated ovarian cancers. Chromosomal anomalies were assessed in 28 specimens with BRCA1 (n=15), BRCA2 (n=12) or BRCA1 and BRCA2 (n=1) mutations using high-density Illumina SNP arrays. The majority (22/28) are serous adenocarcinomas while the remaining samples were either endometroid (2/28) or mixed adenocarcinomas (4/28). The cases harbor BRCA1/BRCA2 mutations from a French Canadian population, which exhibit strong founder effects. Allelic imbalance, copy number differences, intrachromosomal breaks and homozygous deletions were inferred visually using the Genome Viewer module of the BeadStudio software followed by ASCAT analysis. A statistical analysis was used to directly compare genotypes of BRCA1 versus BRCA2 positive samples. TP53 gene mutation status was also assessed. All samples were found to harbor a somatic TP53 mutation comprised of missense (19/28), nonsense (2/28), frame-shift (4/28) and (3/28) splice mutations. The results were compared to independently derived data generated previously from our group, which was largely comprised of sporadic cases (Wojnarowicz et al 2012), and to the genomic data from the Cancer Genome Atlas project (TCGA). The genomic landscapes of BRCA1 and BRCA2 mutated cancers overlap those reported in previous studies. However, there were significant differences in the genomic landscapes involving chromosome 6q between BRCA1 and BRCA2 mutation-positive cancers. This genomic distinction between BRCA1 and BRCA2 ovarian cancer samples may point to a region containing genes important in the etiology or progression of hereditary cancer. Citation Format: Eman AlShehri, Moria Belanger, Suzanna Arcand, Kathleen Klein Oros, Celia Greenwood, Patricia N. Tonin. Characterization of genomic landscapes of BRCA1 and BRCA2 implicated ovarian cancer specimens from a founder french canadian population [abstract]. In: Proceedings of the 10th Biennial Ovarian Cancer Research Symposium; Sep 8-9, 2014; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(16 Suppl):Abstract nr POSTER-TECH-1101.
Unstable Alpha Hemoglobin Stabilizing Protein as a Cause of Thalassemia: Proof of Concept.
Authors: Serge Pissard, Corinne Vasseur, Fabienne Toutain, Muriel Silva, Emmanuelle Faubert-Laugé, Elisa Domingues, Michael Marden, Henri Wajcman, Véronique Baudin-Creuza
Journal: Blood (2009)
P133 A Multidisciplinary Patient Education Programme Significantly Improves Asthma Control and Quality of Life in Patients with Severe Asthma: Abstract P133 Table 1
Authors: RD Daly, LJ Holmes, H Scanlon, D Ryan, RM Niven
Journal: Thorax (2015)

<h3>Background</h3> The impact of severe asthma upon quality of life is significant, as a consequence of unpredictable hospitalisations and life-threatening attacks. It is unknown whether patient education programmes in severe asthma improve self-management, quality of life or measures of asthma control. A 12 week patient education programme was piloted within a severe asthma multi-disciplinary team. Sessions were 2 h duration fortnightly. The aim of the programme was to enable patients to gain greater insight into their disease, treatment options and lifestyle management with emphasis on improving asthma control and quality of life. <h3>Aims</h3> Our aim was to assess the effect of the introduction of this programme upon participant’s asthma control and quality of life. <h3>Methods</h3> Prospective data collection was performed, including Asthma Quality of Life Questionnaire (AQLQ), Asthma Control Questionnaire (ACQ) and Hospital Anxiety and Depression (HAD) at week 1 and 12. Patient Satisfaction Evaluation forms were completed to facilitate ongoing programme development. <h3>Results</h3> 21 patients entered with 16 (76%) completing the 12 week programme (12 female, 4 male). Dropout was attributed to difficulty attending on a regular basis. There was an improvement in mean total AQLQ of 1.3 (minimal clinically important difference &gt;0.5). There was notable improvement in the AQLQ domains; symptoms (0.8) and emotional (0.7). Mean ACQ improved by 0.7 (p &lt; 0.05), mean HAD anxiety and depression scores fell but this did not reach statistical significance (Table 1). <h3>Conclusion</h3> A multidisciplinary patient education group for severe asthma patients significantly improves quality of life and asthma control. Longitudinal studies are required to determine impact upon exacerbations and hospitalisations.
PTH-001 “Prophylactic” placement of self-expandable metal stent in colorectal cancer prior to obstruction: is this of any value?
Authors: S K Butt, K Jaggs, N Van Someren, K Besherdas
Journal: Gut (2010)

<h3>Introduction</h3> Colorectal cancer (CRC) is one of the most prevalent malignancies in the world and is the second most common cancer cause of death in the UK. Colonic obstruction is usually a late presentation of CRC and is more characteristic of an advanced and incurable lesion. 40% of CRC present as a surgical emergency with either obstruction or perforation. Emergency presentation is associated with a poorer outcome. Colonic stents are a routine part of management of CRC, being used for palliation and as a "bridge to surgery" for patients presenting with bowel obstruction thus minimising morbidity and mortality. It can be argued that the tighter the CRC stricture the more difficult the process of placement of colonic stent. For this reason, it has been suggested by some that "prophylactic" stent placement in the palliation of CRC patients who have stricturing but not yet obstruction may be an appropriate step in management. This may reduce failure rate of stent placement during obstruction and thus prevent emergency surgical decompression. <h3>Methods</h3> To aim was to assess the number of patients presenting with a stricturing CRC tumour that subsequently obstructs. This was a retrospective analysis was performed on consecutive patients with CRC during 2006–2007, presenting with a stricture as identified on colonoscopy and deemed for palliation following a multidisciplinary assessment. An analysis of whether or not these patients subsequently developed obstruction was performed. Data were obtained from the Unisoft endoscopy software and a database of patients with CRC. <h3>Results</h3> 17 patients (9 males, mean age of 78 (52 to 96 years)), were found to have a malignant stricturing lesion at colonoscopy and had palliative treatment. Four patients presented with obstruction as part of their symptom complex and underwent successful colonic stent placement. One patient underwent a defunctioning stoma operation for bowel obstruction 1 month following diagnosis. In the 12 cases (70%) that were not stented, none re-presented with bowel obstruction. 16 /17 patients died from causes unrelated to bowel obstruction, with all dying within 18 months due to disease progression and chemotherapy related complications. One patient who initially presented with obstructive symptoms and was subsequently stented is still alive to date. <h3>Conclusion</h3> The majority (70%) of CRC presenting with stricturing at colonoscopy do not require treatment for obstruction (ie, stenting or operation) and seem to die from disease progression prior to occurrence of clinical obstruction. "Prophylactic" stent placement to prevent obstruction, when CRC presents with a stricturing lesion is not suggested by this study.
First Clinical Evidence of In Vivo Natural Killer (NK) Cell Modulation in Chronic Lymphocytic Leukemia (CLL) Patients (pts) Treated with Lenalidomide (L).
Authors: Swaminathan Padmanabhan, Noreen Ersing, Paul K. Wallace, Kena C. Miller, Laurie Musiel, Micheal Rickert, Asher Alban Chanan-Khan
Journal: Blood (2006)
Abstract 636: Next-generation site-specific antibody-drug conjugates using the SMARTagTM technology platform
Authors: Romas Kudirka
Journal: Cancer Research (2015)

Abstract The two clinically-approved antibody-drug conjugates, AdcetrisTM and KadcylaTM, demonstrate that targeting cytotoxic payloads directly to tumors is an effective clinical approach. However, at the molecular level, these therapeutics are composed of heterogeneous mixtures resulting from the nonselective ligation of cytotoxic payload to cysteine and lysine residues, respectively. The nonselective ligation approaches used to generate these two ADCs render it difficult to optimize their biological, physical, and pharmacological properties. Redwood Bioscience creates site-selective, stable linkages that allow us to design ADCs with enhanced efficacy, safety, and pharmacokinetics. Additionally, we are able to control payload stoichiometry and placement. Redwood Bioscience creates homogeneous ADCs using the SMARTagTM technology, in which a genetically encoded 5 amino acid “aldehyde-tag” sequence contains a cysteine that is cotranslationally converted to formylglycine via an enzymatic transformation. This method affords control over the placement of the reactive formylglycine aldehyde side chain, which can then be ligated using carbonyl bioconjugation methods. Here, we will present our novel protein modification platform—including our new conjugation chemistries and linker libraries—and its application to ADC generation. We will address SMARTagTM ADC safety, pharmacokinetics, and efficacy in preclinical tumor models, and discuss how these parameters are impacted by linker selection and payload placement on the antibody. Citation Format: Romas Kudirka. Next-generation site-specific antibody-drug conjugates using the SMARTagTM technology platform. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 636. doi:10.1158/1538-7445.AM2015-636
A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation study
Authors: Chantal B van Houten, Joris A H de Groot, Adi Klein, Isaac Srugo, Irena Chistyakov, Wouter de Waal, Clemens B Meijssen, Wim Avis, Tom F W Wolfs, Yael Shachor-Meyouhas, Michal Stein, Elisabeth A M Sanders, Louis J Bont
Journal: The Lancet Infectious Diseases (2016)
Abstract 1386: KLF5 inhibits angiogenesis in PTEN-deficient prostate cancer by attenuating AKT activation and subsequent HIF1α accumulation
Authors: Xinpei Ci, Changsheng Xing, Baotong Zhang, Zhiqian Zhang, Jenny Jianping Ni, Wei Zhou, Jin-Tang Dong
Journal: Cancer Research (2015)

Abstract Background: KLF5 is a basic transcriptional factor that regulates multiple physiopathological processes. Our recent study showed that deletion of Klf5 in mouse prostates promotes tumorigenesis initiated by the deletion of Pten. While molecular characterization of Klf5-null tumors suggested that angiogenesis was partially responsible for tumor promotion, the precise function and mechanism of KLF5 deletion in prostate tumor angiogenesis remain unclear. Results: Using histological staining of Pten-null mouse prostates, we observed that deletion of Klf5 significantly increased the number of microvessels, which was accompanied by the upregulation of multiple angiogenesis-related genes based on microarray analysis with MetaCore software. In human umbilical vein endothelial cells (HuVECs), tube formation and migration, both of which are indicators of angiogenic activities, were decreased by conditioned media from PC-3 and DU 145 human prostate cancer cells with KLF5 overexpression, but increased by media from cells with KLF5 knockdown. HIF1α, a key angiogenesis inducer, was upregulated by KLF5 loss at the protein but not the mRNA level in both mouse tissues and human cell lines, as examined by immunohistochemical staining, real-time RT-PCR and Western blotting. Consistently, KLF5 loss also upregulated VEGF and PDGF, two pro-angiogenic mediators of HIF1α function, as analyzed by immunohistochemical staining in mouse tissues and ELISA in conditioned media. Mechanistically, AKT activity, which caused the accumulation of HIF1α, was increased by KLF5 knockout or knockdown but decreased by KLF5 overexpression. Consistently, PI3K/AKT inhibitors abolished the effects of KLF5 knockdown on angiogenic activity, HIF1α accumulation, and VEGF and PDGF expression. Conclusion: KLF5 loss enhances tumor angiogenesis by attenuating PI3K/AKT signaling and subsequent accumulation of HIF1α in PTEN deficient prostate tumors. Citation Format: Xinpei Ci, Changsheng Xing, Baotong Zhang, Zhiqian Zhang, Jenny Jianping Ni, Wei Zhou, Jin-Tang Dong. KLF5 inhibits angiogenesis in PTEN-deficient prostate cancer by attenuating AKT activation and subsequent HIF1α accumulation. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1386. doi:10.1158/1538-7445.AM2015-1386
Abstract 2715: Hepatotoxicity and oxidative stress biomarker study of peg-coated and non-coated gold nanoparticles in Sprague-Dawley rats
Authors: Anita K. Patlolla, Myeisha Fountain, Paul Tchounwou
Journal: Cancer Research (2015)

Abstract Nanoparticles (NPs) offer a great possibility for biomedical application, not only to deliver pharmaceutics, but also to be used as novel diagnostic and therapeutic approaches. Currently, there are no data available regarding to what extent the degree of the toxicity and the accumulation of gold nanoparticles (GNPs) are present in in vivo model. The aim of this study was to assess the effects, after oral administration, of poly-ethylene-glycol (PEG) coated and non-coated GNPs on various hepatotoxicity and oxidative stress markers such as alanine (ALT), aspartate aminotransferases and alkaline phosphatase, lipid hydro peroxide (LHP) in the mouse model. Sprague -Dawley rats were exposed to four different concentrations of PEG-coated and non-coated GNPs (12.5, 25, 50 and 100 mg/kg BW) and a control. Samples were collected 24 hours after the last treatment following standard protocols. Exposure to PEG-coated and non-coated GNPs enhanced the activities of serum amino-transferases (ALT/AST), alkaline phosphatases (ALP) and concentration of lipid hydro peroxide compared to control. However, PEG-coated GNPs demonstrated enhanced hepatotoxic effect than non-coated GNPs. The scientific findings reported here suggest that both GNPs have the potential to induce hepatotoxicity in Sprague-Dawley rats through activation of the mechanisms of oxidative stress at a higher level of exposure. However, more studies to clarify the role of encapsulation in the in vivo toxicity of GNPs, are required and parallel comparison is preferred. Keywords: gold nanoparticle (GNP), poly-ethylene-glycol, lipid hydroperoxide, serum aminotransferases, alkaline phosphatases, Sprague-Dawley rats, hepatotoxicity. Citation Format: Anita K. Patlolla, Myeisha Fountain, Paul Tchounwou. Hepatotoxicity and oxidative stress biomarker study of peg-coated and non-coated gold nanoparticles in Sprague-Dawley rats. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2715. doi:10.1158/1538-7445.AM2015-2715
Early Human Herpes Virus Type 6 Reactivation in Patients Undergoing Allogeneic Stem Cell Transplantation (allo-SCT).
Authors: Remy Dulery, Anny Dewilde, Julie Gay, Julien Rossignol, Louis Terriou, Valerie Coiteux, Jean-Pierre Jouet, Ibrahim Yakoub-Agha
Journal: Blood (2009)
Bone morphogenic protein 4 (BMP-4) induced by NDRG2 expression inhibits metastatic potential of malignant breast cancer cells
Authors: Soo-Kyung Shon, Yongjin Park, Aeyung Kim, Jong-Seok Lim
Journal: Clinical Cancer Research (2007)

C49   NDRG2 (N-myc downstream-regulated genes) belongs to the NDRG family, a new family of differentiation-related genes, and it is highly expressed in the adult brain, salivary gland, and skeletal muscle. Recently, it has been shown that NDRG2 down-regulation is involved in the development of aggressive forms of brain cancer. In the present study, in order to investigate the function of NDRG2 gene, the gene was overexpressed in NDRG2-negative MDA-MB-231 breast cancer cell line and stable transfectants were established. NDRG2-positive transfectants showed cell cycle arrest and decreased migration capacity compared to wild type cell line. The transcriptional expression and activity of several MMPs were also modulated in NDRG2-positive transfectants. Moreover, we selected a few of interesting genes by DEG screening that makes it possible compare wild type cell line with NDRG2-positive transfectants based on gene expression. Among these differential genes, we clearly observed the specific induction of BMP-4 expression in NDRG2-overexpressed cell line. Here, we found that an anti-tumor cytokine, BMP4, inhibits migration, invasion, and MMP9 activity of MDA-231 cell line. BMP4 also inhibits the transcriptional activity of MMP9. In addition, the inhibition of phorbol myristate acetate (PMA)-induced MMP9 activity by BMP-4 was observed in MCF-7 cell line. These results suggest that the suppression of MMP9 expression, at least in part, contributes to the antitumor activity of BMP4. Taken together, our data indicate that over-expression of NDRG2 as a tumor suppressor gene may contribute to the delayed tumor progression and further studies on BMP-4 activity in relation to NDRG2 expression will provide more information for effective growth control and migration inhibition of breast cancer.